Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled study of milvexian for stroke prevention after acute ischemic stroke or high-risk transient ischemic attack
2022-501176-26-00Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 46
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke and transient ischaemic attack (TIA) comparing Milvexian plus antiplatelet therapy with Placebo plus antiplatelet therapy (2 arms). Primary endpoint: Time to first occurrence of ischemic stroke. Started Aug 2023; status: completed.
02
Drugs
milvexian
03
Conditions
ischemic stroketransient ischaemic attack (TIA)
Beyond the preview
Go deeper on 2022-501176-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501176-26-00.